Phaseline

Targets › SLC31A2

SLC31A2 (Protein SLC31A2): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 2; Oncology; next expected readout May 2027.

Does not function as a copper(1+) importer in vivo (By similarity). However, in vitro functions as a low-affinity copper(1+) importer. (UniProt, O15432)

Open in Phaseline: the race on SLC31A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Privo TechnologiesPRV111 (Cisplatin Transmucosal System)
Transmucosal cisplatin patch delivery system
SLC31A2Phase 2Oral Squamous Cell CarcinomaMay 2027

Conditions

Oral Squamous Cell Carcinoma (3)

Modalities

mixed (1)

Companies

Privo Technologies (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.